8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 25, 2026·SEC
Recursion Pharmaceuticals, Inc.(RXRX)Earnings, Financials & Key Ratios
RXRX•NASDAQ
Price updated Jun 19, 2026
AboutRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$75M+26.9%
- EBITDA-$564M-27.6%
- Net Income-$645M-39.1%
- EPS (Diluted)-1.44+14.8%
- Gross Margin-61.96%-368.0%
- EBITDA Margin-755.79%-0.5%
- Operating Margin-867.87%-6.6%
- Net Margin-863.35%-9.6%
- ROE-59.54%+3.8%
RXRX Key Insights
Recursion Pharmaceuticals, Inc. (RXRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 85.4%
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Profits declining 49.3% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 63.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RXRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RXRX Price & Volume
Recursion Pharmaceuticals, Inc. (RXRX) stock price & volume — 10-year historical chart
Loading chart...
RXRX Growth Metrics
Recursion Pharmaceuticals, Inc. (RXRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years85.36%
3 Years23.46%
TTM10.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.2%
Return on Capital
10 Years-51.48%
5 Years-49.74%
3 Years-54.32%
Last Year-50.1%
RXRX Recent Earnings
Recursion Pharmaceuticals, Inc. (RXRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.22+26.7%
$0.30
Rev
$6M-60.1%
$16M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.21+25.0%
$0.28
Rev
$35M+44.0%
$25M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.36+5.3%
$0.38
Rev
$5M-78.9%
$25M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.41-17.1%
$0.35
Rev
$19M-4.1%
$20M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.22vs $0.30+26.7% | $6Mvs $16M-60.1% |
| Q1 2026 | Feb 25, 2026 | $0.21vs $0.28+25.0% | $35Mvs $25M+44.0% |
| Q4 2025 | Nov 5, 2025 | $0.36vs $0.38+5.3% | $5Mvs $25M-78.9% |
| Q3 2025 | Aug 5, 2025 | $0.41vs $0.35-17.1% | $19Mvs $20M-4.1% |
Based on last 12 quarters of dataView full earnings history →
RXRX Peer Comparison
Recursion Pharmaceuticals, Inc. (RXRX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SDGR | 1.18B | 15.76 | -11.18 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABCL | 1.69B | 5.53 | -11.29 | 160.56% | -181.75% | -14.22% | 0.13 | |
 RLAY | 3B | 15.88 | -9.86 | 53.44% | -25.54% | -43.94% | 0.06 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 |
Compare RXRX vs Peers
Recursion Pharmaceuticals, Inc. (RXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RXRX Income Statement
Recursion Pharmaceuticals, Inc. (RXRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.71M | 3.41M | 10M | 39.68M | 43.88M | 58.84M | 74.68M | 66.29M |
Revenue Growth % | - | 99.47% | 193% | 296.81% | 10.57% | 34.1% | 26.92% | 10.96% |
Cost of Goods Sold | 45.81M | 0 | 0 | 48.27M | 42.59M | 45.24M | 120.95M | 89.12M |
COGS % of Revenue | 2677.32% | - | - | 121.66% | 97.06% | 76.88% | 161.96% | - |
Gross Profit | -44.1M▲ 0% | 3.41M▲ 107.7% | 10M▲ 193.0% | -8.59M▼ 185.9% | 1.29M▲ 115.0% | 13.6M▲ 955.2% | -46.27M▼ 440.2% | -22.83M▲ 0% |
Gross Margin % | -2577.32% | 100% | 100% | -21.66% | 2.94% | 23.12% | -61.96% | -34.44% |
Gross Profit Growth % | - | 107.74% | 193% | -185.94% | 115% | 955.16% | -440.22% | - |
Operating Expenses | 64.15M | 88.03M | 192.78M | 237.13M | 351.35M | 492.61M | 601.86M | 562.44M |
OpEx % of Revenue | 3749.39% | 2579.2% | 1927.75% | 597.6% | 800.78% | 837.21% | 805.91% | - |
Selling, General & Admin | 18.95M | 25.26M | 57.68M | 81.6M | 110.82M | 178.18M | 176.59M | 156.53M |
SG&A % of Revenue | 1107.6% | 740.05% | 576.82% | 205.64% | 252.58% | 302.83% | 236.46% | - |
Research & Development | 45.81M | 63.32M | 135.27M | 155.7M | 241.23M | 314.42M | 425.27M | 420.93M |
R&D % of Revenue | 2677.32% | 1855.23% | 1352.71% | 392.37% | 549.79% | 534.38% | 569.45% | - |
Other Operating Expenses | -608K | -549K | -178K | -162K | -699K | 0 | 0 | -1.12M |
Operating Income | -62.44M▲ 0% | -84.61M▼ 35.5% | -182.78M▼ 116.0% | -245.73M▼ 34.4% | -350.06M▼ 42.5% | -479M▼ 36.8% | -648.13M▼ 35.3% | -585.27M▲ 0% |
Operating Margin % | -3649.39% | -2479.2% | -1827.75% | -619.26% | -797.84% | -814.09% | -867.87% | -882.92% |
Operating Income Growth % | - | -35.51% | -116.01% | -34.44% | -42.46% | -36.83% | -35.31% | - |
EBITDA | -58.9M | -80.67M | -174.37M | -233.97M | -325.66M | -442.51M | -564.43M | -501.23M |
EBITDA Margin % | -3442.31% | -2363.67% | -1743.7% | -589.63% | -742.22% | -752.07% | -755.79% | -756.13% |
EBITDA Growth % | - | -36.97% | -116.15% | -34.18% | -39.19% | -35.88% | -27.55% | 4.63% |
D&A (Non-Cash Add-back) | 3.54M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M | 83.7M | 84.04M |
EBIT | -61.88M | -85.65M | -183.53M | -239.42M | -332.03M | -463.22M | -643.09M | -570.27M |
Net Interest Income | 1.11M | -1.02M | -2.88M | 6.2M | 19.02M | 14.19M | 20.98M | 21.53M |
Interest Income | 1.74M | 336K | 73K | 6.25M | 19.12M | 15.76M | 22.79M | 23.19M |
Interest Expense | 635K | 1.36M | 2.95M | 55K | 97K | 1.57M | 1.81M | 1.66M |
Other Income/Expense | 562K | -2.39M | -3.7M | 6.25M | 17.93M | 14.22M | 3.24M | 20.91M |
Pretax Income | -61.88M▲ 0% | -87.01M▼ 40.6% | -186.48M▼ 114.3% | -239.48M▼ 28.4% | -332.13M▼ 38.7% | -464.79M▼ 39.9% | -644.89M▼ 38.8% | -564.36M▲ 0% |
Pretax Margin % | -3616.54% | -2549.25% | -1864.79% | -603.5% | -756.97% | -789.93% | -863.53% | -851.37% |
Income Tax | 0 | 0 | 0 | 0 | -4.06M | -1.13M | -136K | -4.58M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 1.22% | 0.24% | 0.02% | 0.81% |
Net Income | -62.52M▲ 0% | -87.01M▼ 39.2% | -186.48M▼ 114.3% | -239.48M▼ 28.4% | -328.07M▼ 37.0% | -463.66M▼ 41.3% | -644.76M▼ 39.1% | -559.78M▲ 0% |
Net Margin % | -3654.3% | -2549.25% | -1864.79% | -603.5% | -747.71% | -788.02% | -863.35% | -844.46% |
Net Income Growth % | - | -39.15% | -114.33% | -28.42% | -36.99% | -41.33% | -39.06% | 2.58% |
Net Income (Continuing) | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M | -559.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.37▲ 0% | -0.52▼ 40.6% | -1.05▼ 100.1% | -1.36▼ 29.5% | -1.58▼ 16.2% | -1.69▼ 7.0% | -1.44▲ 14.8% | -1.06▲ 0% |
EPS Growth % | - | -40.62% | -100.08% | -29.52% | -16.18% | -6.96% | 14.79% | 32.2% |
EPS (Basic) | -0.37 | -0.52 | -1.05 | -1.36 | -1.58 | -1.69 | -1.44 | - |
Diluted Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M | 529.3M |
Basic Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M | 529.3M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RXRX Balance Sheet
Recursion Pharmaceuticals, Inc. (RXRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 76.4M | 266.44M | 534.72M | 569.81M | 438.14M | 714.27M | 812.85M | 709.56M |
Cash & Short-Term Investments | 69.88M | 262.13M | 516.56M | 549.91M | 391.56M | 594.35M | 743.29M | 654.47M |
Cash Only | 69.88M | 262.13M | 285.12M | 549.91M | 391.56M | 594.35M | 743.29M | 654.47M |
Short-Term Investments | 0 | 0 | 231.45M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 151K | 156K | 9.09M | 2.75M | 3.09M | 49.17M | 24.65M | 13.59M |
Days Sales Outstanding | 32.21 | 16.68 | 331.79 | 25.32 | 25.74 | 304.99 | 120.47 | 112.53 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 6.36M | 4.16M | 9.07M | 17.15M | 43.48M | 70.75M | 44.9M | 41.5M |
Total Non-Current Assets | 25.03M | 32.15M | 75.63M | 131.47M | 215.56M | 734.33M | 661.28M | 629.97M |
Property, Plant & Equipment | 24.37M | 25.97M | 64.72M | 121.45M | 120.17M | 233.21M | 169.48M | 157.32M |
Fixed Asset Turnover | 0.07x | 0.13x | 0.15x | 0.33x | 0.37x | 0.25x | 0.44x | 0.38x |
Goodwill | 0 | 801K | 801K | 801K | 52.06M | 148.87M | 162.16M | 160.17M |
Intangible Assets | 0 | 1.69M | 1.39M | 1.31M | 36.44M | 335.86M | 309.9M | 294.07M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 5.63M | 0 | 5.63M |
Other Non-Current Assets | 663K | 3.69M | 8.72M | 7.92M | 6.89M | 8.82M | 18.79M | 17.44M |
Total Assets | 101.43M▲ 0% | 298.58M▲ 194.4% | 610.35M▲ 104.4% | 701.29M▲ 14.9% | 653.7M▼ 6.8% | 1.45B▲ 121.6% | 1.47B▲ 1.8% | 1.34B▲ 0% |
Asset Turnover | 0.02x | 0.01x | 0.02x | 0.06x | 0.07x | 0.04x | 0.05x | 0.05x |
Asset Growth % | - | 194.37% | 104.41% | 14.9% | -6.79% | 121.6% | 1.76% | 164.89% |
Total Current Liabilities | 6.68M | 23.1M | 46.66M | 100.27M | 93.17M | 187.47M | 147.71M | 129.7M |
Accounts Payable | 1.26M | 1.07M | 2.82M | 4.59M | 3.95M | 21.61M | 18.12M | 20.35M |
Days Payables Outstanding | 10.05 | - | - | 34.67 | 33.88 | 174.38 | 54.67 | 73.43 |
Short-Term Debt | 77K | 1.07M | 90K | 97K | 41K | 22.22M | 21.75M | 22.35M |
Deferred Revenue (Current) | 0 | 10M | 10M | 56.73M | 36.43M | 61.77M | 37.6M | 157.45M |
Other Current Liabilities | 1.7M | 3.08M | 11.74M | 20.43M | 23.75M | 81.87M | 70.23M | 54.2M |
Current Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x | 5.50x | 5.47x |
Quick Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x | 5.50x | 5.47x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 39.11 |
Total Non-Current Liabilities | 219.01M | 481.77M | 20.75M | 115.22M | 97.09M | 226.34M | 195.56M | 185.05M |
Long-Term Debt | 12.42M | 11.41M | 633K | 536K | 1.1M | 19.02M | 56.21M | 50.02M |
Capital Lease Obligations | 3.21M | 2.71M | 9.34M | 44.42M | 43.41M | 67.25M | 0 | 53.4M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.34M | 16.57M | 23.25M | 88.63M |
Other Non-Current Liabilities | 203.39M | 450.99M | 4.11M | 0 | 0 | 4.73M | 116.09M | 116.75M |
Total Liabilities | 225.7M | 504.87M | 67.41M | 215.48M | 190.26M | 413.82M | 343.26M | 314.75M |
Total Debt | 16.17M | 15.66M | 11.48M | 51.01M | 50.67M | 108.49M | 77.97M | 72.38M |
Net Debt | -53.71M | -246.46M | -273.64M | -498.91M | -340.89M | -485.86M | -665.33M | -582.1M |
Debt / Equity | - | - | 0.02x | 0.10x | 0.11x | 0.10x | 0.07x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 1.16x |
Interest Coverage | -97.45x | -62.98x | -62.17x | -4353.11x | -3423.00x | -294.67x | -355.30x | -342.92x |
Total Equity | -124.27M▲ 0% | -206.29M▼ 66.0% | 542.94M▲ 363.2% | 485.81M▼ 10.5% | 463.44M▼ 4.6% | 1.03B▲ 123.3% | 1.13B▲ 9.3% | 1.02B▲ 0% |
Equity Growth % | - | -66.01% | 363.19% | -10.52% | -4.6% | 123.28% | 9.29% | 175.86% |
Book Value per Share | -0.75 | -1.24 | 3.19 | 2.77 | 2.23 | 3.77 | 2.53 | 1.94 |
Total Shareholders' Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B | 1.13B | 1.02B |
Common Stock | 0 | 0 | 2K | 2K | 2K | 4K | 5K | 5K |
Retained Earnings | -126.59M | -213.6M | -400.08M | -639.56M | -967.62M | -1.43B | -2.08B | -2.19B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -126K | 0 | 0 | -7.64M | 36.72M | 26.66M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RXRX Cash Flow Statement
Recursion Pharmaceuticals, Inc. (RXRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -57.04M | -45.4M | -158.61M | -83.52M | -287.78M | -359.17M | -371.81M | -320.95M |
Operating CF Margin % | -3333.84% | -1330.18% | -1586.14% | -210.49% | -655.89% | -610.44% | -497.86% | - |
Operating CF Growth % | - | 20.41% | -249.38% | 47.34% | -244.55% | -24.81% | -3.52% | 7.52% |
Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M | -559.78M |
Depreciation & Amortization | 2.49M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M | 83.7M | 84.04M |
Stock-Based Compensation | 1.39M | 4.29M | 14.84M | 27.91M | 53.5M | 81.69M | 111.22M | 75.17M |
Deferred Taxes | 0 | 0 | 827K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 555K | 2.54M | 4.1M | 11.37M | 12.64M | 24.31M | 64.34M | 67.88M |
Working Capital Changes | 408K | 30.83M | -306K | 104.92M | -50.26M | -38M | 13.69M | 11.73M |
Change in Receivables | 605K | -1.12M | 114K | -2K | 0 | -6.07M | 32.94M | 42.85M |
Change in Inventory | 0 | 0 | 7.83M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -340K | -185K | 1.75M | 1.77M | -987K | 6.43M | -2.62M | -4.24M |
Cash from Investing | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M | 260.06M | -16.87M | -9.94M |
Capital Expenditures | -3.91M | -5.83M | -39.8M | -37.06M | -11.96M | -13.7M | -6.47M | -4.97M |
CapEx % of Revenue | 228.52% | 170.85% | 397.98% | 93.39% | 27.25% | 23.28% | 8.66% | 7.51% |
Acquisitions | 0 | -2.6M | 231.95M | 0 | 1.84M | 277.1M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | -309K | -231.95M | -300K | -597K | -3.35M | -6.6M | -2.16M |
Cash from Financing | 120.41M | 246.13M | 458.54M | 154.34M | 140.13M | 304.12M | 521.53M | 477.54M |
Debt Issued (Net) | 705K | 6.32M | -12.8M | -90K | -766K | -4.44M | -8.43M | -8.59M |
Equity Issued (Net) | 119.92M | 239.13M | 462.9M | 143.71M | 128.09M | 300.42M | 532.96M | 491.38M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -210K | 681K | 8.44M | 10.72M | 12.81M | 8.14M | -3M | -5.25M |
Net Change in Cash | 59.46M▲ 0% | 192M▲ 222.9% | 28.18M▼ 85.3% | 263.76M▲ 835.9% | -157.69M▼ 159.8% | 201.6M▲ 227.8% | 150.9M▼ 25.1% | 156.86M▲ 0% |
Free Cash Flow | -60.95M▲ 0% | -52.13M▲ 14.5% | -198.41M▼ 280.6% | -120.88M▲ 39.1% | -300.33M▼ 148.4% | -372.87M▼ 24.2% | -378.28M▼ 1.5% | -325.85M▲ 0% |
FCF Margin % | -3562.36% | -1527.51% | -1984.12% | -304.64% | -684.5% | -633.71% | -506.52% | -491.56% |
FCF Growth % | - | 14.47% | -280.58% | 39.07% | -148.45% | -24.15% | -1.45% | 18.75% |
FCF per Share | -0.37 | -0.31 | -1.17 | -0.69 | -1.44 | -1.36 | -0.85 | -0.62 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x | 0.58x | 0.58x |
Interest Paid | 485K | 989K | 0 | 55K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RXRX Key Ratios
Recursion Pharmaceuticals, Inc. (RXRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -110.79% | -46.56% | -69.12% | -61.9% | -59.54% | -54.32% |
Return on Invested Capital (ROIC) | - | - | -143.87% | -479.79% | -107.01% | -95.83% | -94.57% |
Gross Margin | 100% | 100% | -21.66% | 2.94% | 23.12% | -61.96% | -34.44% |
Net Margin | -2549.25% | -1864.79% | -603.5% | -747.71% | -788.02% | -863.35% | -844.46% |
Debt / Equity | - | 0.02x | 0.10x | 0.11x | 0.10x | 0.07x | 0.07x |
Interest Coverage | -62.98x | -62.17x | -4353.11x | -3423.00x | -294.67x | -355.30x | -342.92x |
FCF Conversion | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x | 0.58x | 0.58x |
Revenue Growth | 99.47% | 193% | 296.81% | 10.57% | 34.1% | 26.92% | 10.96% |
Related:RXRX Dividend History·RXRX Revenue History·RXRX Price History·RXRX P/E History·RXRX Financial Ratios·RXRX Institutional Holders
RXRX SEC Filings & Documents
Recursion Pharmaceuticals, Inc. (RXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
RXRX Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (RXRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Recursion Pharmaceuticals, Inc. (RXRX) reported $66.3M in revenue for fiscal year 2025. This represents a 3774% increase from $1.7M in 2019.
Recursion Pharmaceuticals, Inc. (RXRX) grew revenue by 26.9% over the past year. This is strong growth.
Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $559.8M for fiscal year 2025.
Dividend & Returns
Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.
Recursion Pharmaceuticals, Inc. (RXRX) had negative free cash flow of $325.8M in fiscal year 2025, likely due to heavy capital investments.